Reuters logo
BRIEF-Mallinckrodt licenses inhaled xenon gas therapy development product
October 2, 2017 / 10:53 AM / 3 months ago

BRIEF-Mallinckrodt licenses inhaled xenon gas therapy development product

Oct 2 (Reuters) - Mallinckrodt Plc

* Mallinckrodt Plc says ‍under terms of agreement, later today Mallinckrodt will pay $10 million upfront with cash on hand​

* Mallinckrodt - anticipates dilution of $0.10 to $0.15 to adjusted diluted earnings per share for rest of 2017, modestly lower in 2018 from deal​

* Mallinckrodt Plc says ‍will make additional payments of up to $25 million dependent on achievement of clinical, regulatory and sales milestones​

* Mallinckrodt Plc - ‍FDA Special Protocol Assessment approved for Phase 3 trial to begin early 2018​

* Mallinckrodt - ‍NeuroproteXeon to get upfront payment of $10 million in cash on hand from co, with potential additional payments of up to $25 million​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below